Technologies du CNRS

Trouvez les meilleures technologies du CNRS pour mener à bien votre projet d’innovation.

Les brevets les plus récents

Vous êtes un chercheur ?

Nous pouvons vous accompagner sur toute votre
démarche de transfert de technologies.

Voir tous nos services

Vous êtes un industriel ?

Grâce à notre expérience, nos réseaux et notre connaissance de l’écosystème de l’innovation nous vous accompagnons tout au long de votre projet.

Nous contacter

Découvrez les technologies du CNRS

Voir nos actualités et rendez-vous

Rencontrez l’équipe


LLT-1 antibodies with functional properties



Statut des brevets

Priority patent application EP10167668, filed in June 29, 2010,
Priority patent application EP10168095, filed in July 1st, 2010
Priority patent application EP10169409 filed in July 13, 2010


Véronique BRAUD

Statut commercial

Research agreement, exclusive or non exclusive licenses




The discovery that Lectin-Like Transcript 1 (LLT1), also known as C-type lectin domain family 2 member D (CLEC2D), is a ligand for the CD161 receptor, also known as NKRP1A, has led to explore several approches for modulating the activities of cells of the immune system in the purpose of disease treatment. The inventors propose a new approch based on the use of monoclonal antibodies (Mab).
Biological therapeutics are now available for the treatment of certain autoimmune and chronic inflammatory diseases and/or cancer. But there is still a need for alternative biological medicaments which specifically target pathological tissue, which do not affect healthy tissue, which result in less severe side effects, which result in fewer side effects, which may be used long-term, which do not result in the formation of inhibitors. The current invention relates to these unmet needs amongst patients with cancer, and in those with autoimmune and chronic inflammatory diseases.


The present invention relates to the characterization of monoclonal antibodies that are capable of specifically binding to LLT1, that block the interaction between LLT1 and its receptor CD161 and that have depleting properties in vitro and in vivo. The present invention also relates to polynucleotides encoding such antibodies and cells expressing such antibodies. These Mab have utility in the diagnosis and treatment of cancer and autoimmune/chronic inflammatory diseases, in which LLT1- and CD161- expressing cells play a role in disease pathogenesis.


The antibodies described in this invention have the potential to modulate immune responses through blocking of the interaction between LLT1 and CD161. The antibodies may be used to stimulate NK cell-mediated anti-tumoral activity or to decrease T cell activation. The antibodies have depleting properties in vitro and in vivo, facilitating the removal of LLT1-expressing cells by antibody-dependent cell-mediated cytotoxicity (ADCC). The antibodies may also be used for diagnosis.


This invention could be used for the treatment of immune–based diseases, mainly cancer and inflammatory/autoimmune disorders, involving LLT1- and CD161- expressing cells in their pathogenesis.

This invention could be useful for the diagnosis of cancer and more specifically B cell non-Hodgkin lymphomas.


The inventors have developed murine and chimeric human antibody molecules that specifically bind to LLT1.
They have demonstrated using in vitro assays that the antibodies block the interaction between LLT1 and CD161, thereby stimulating the cytokine production and the cytotoxicity of NK cells and inhibiting the proliferation and the cytokine production of T cells.
They have demonstrated using in vitro assays that the antibodies facilitate the removal of LLT1-expressing cells by antibody-dependent cell-mediated cytotoxicity (ADCC). Preliminary pre-clinical tests in mice xenografted with human B cell lymphomas show in vivo efficacy alone and in combination with rituximab (anti-CD20).

For further information, please contact us (Ref 03864-01)

Besoin de plus d'informations ?

Nous contacter


  • Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.

Les brevets les plus récents